Myristoylated derivatives of 2',3'-didehydro-2',3'-dideoxythymidine (stavudine) bi-functional prodrugs with potent anti-HIV-1 activity and low cytotoxicity. 2014

Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
Nucleic Acids & Antiviral Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, India. rksinghsrk@gmail.com.

BACKGROUND To improve in vitro antiviral activity and selectivity of stavudine (d4T), a range of its bi-functional prodrugs, 5'-O-myristoylated derivatives, have been synthesized. METHODS Stavudine 5'-O-myristoylated esters were synthesized using modified Parang's procedure. The cytotoxicity and anti-HIV activity was evaluated in the established MT-4 cell line. The level of p24 protein in culture medium was assayed, and EC50 and EC90 values were determined. RESULTS Excellent anti-HIV activity was obtained for stavudine derivatives 2',3'-didehydro-2',3'-dideoxy-5'-O-(11-thioethylundecanoyl) thymidine, 2',3'-didehydro-2',3'-dideoxy-5'-O-(12-thioethyldodecanoyl) thymidine and 5'-O-(12-azidododecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine with C10 and C11 alkyl chains bearing thioethyl- and azido- substituents. These prodrugs were more potent than the parent stavudine, as is clear from their EC50 values: 2',3'-didehydro-2',3'-dideoxy-5'-O-(11-thioethylundecanoyl) thymidine (R=CO(CH2)10SC2H5, EC50 0.06 μM), 2',3'-didehydro-2',3'-dideoxy-5'-O-(12-thioethyldodecanoyl) thymidine (R=CO(CH2)11SC2H5, EC50 0.09 μM) and 5'-O-(12-azidododecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine (R=CO(CH2)11N3, EC50 0.06 μM), while 50% cytotoxic concentration was >16.65 μM, >7.5 μM and >18.53 μM, respectively. CONCLUSIONS Overall data demonstrate that compounds 2',3'-didehydro-2',3'-dideoxy-5'-O-(11-thioethylundecanoyl) thymidine, 2',3'-didehydro-2',3'-dideoxy-5'-O-(12-thioethyldodecanoyl) thymidine and 5'-O-(12-azidododecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine are very potent and selective anti-HIV agents and could be useful in treatment of HIV infections of the central nervous system.

UI MeSH Term Description Entries
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
July 1999, Antiviral research,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
February 1991, Biochemical and biophysical research communications,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
April 1989, The Journal of biological chemistry,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
November 1994, Journal of immunological methods,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
June 1995, Antiviral research,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
January 2002, Organic letters,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
November 1996, Molecular pharmacology,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
April 2011, Bioorganic & medicinal chemistry letters,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
December 1993, Journal of pharmaceutical sciences,
Ramendra K Singh, and Agnieszka Miazga, and Aleksandra Dąbrowska, and Andrzej Lipniacki, and Andrzej Piasek, and Tadeusz Kulikowski, and David Shugar
July 1999, Bioorganicheskaia khimiia,
Copied contents to your clipboard!